Wound Management Technologies Addresses Multi Billion Dollar Wound Care Market With CellerateRX

Wound Management Technologies, Inc., a rapidly growing provider of advanced biotech medical devices, and presenting company at OneMedForum NY 2011, recently announced the publication of an interview of its President Deborah Jenkins Hutchinson by CEOCFOInterviews.com, a weekly web publication consisting of interviews with CEOs and CFOs of publicly traded growth companies.

Topics within the interview, conducted by Lynn Fosse, Senior Editor, CEOCFOinterviews.com include why Ms. Jenkins Hutchinson joined the company, how and why the company’s FDA approved flagship product, CellerateRXÒ, has become a primary treatment for all types of wounds (except 3rd degree burns) and the reasons why the investment community is beginning to take notice of the public company’s common stock (WNDM: OTCQB).

Wound Management’s lead product, CellerateRX, is a unique, patented activated collagen that addresses the expanding diabetes and greater wound care markets. The company is also developing a resorbable bone wax and bone void filler product line. In 2007, the U.S. Advanced Wound Care market alone accounted for $3 billion and is projected to double to $6.0 billion by 2013.

In the interview, the Wound Management President summarizes the Company’s progress by stating, “Wound Management Technologies is growing and hitting its milestones. It will be cash flow positive, and it will be profitable.  We are doing what we said we were going to do and we believe Wound Management Technologies is going to emerge into quite a strong company.”

The interview can be accessed at either; http://ceocfointerviews.com/interviews/WNDM-WoundManagement11.htm or within the newly reconfigured Wound Management Technologies website http://www.wmgtech.com.

The company recently reported their cash position at an all time high. For the three-month period ending March 31, 2011, revenue was $935,412, a 1,303% increase over first quarter 2010 net revenue of $66,960.  The increase in revenue was primarily attributable to enhanced sales efforts in 2010, which continued into the first quarter of 2011.  Cash flow from operations at 3/31/11 was positive for the first time in the company’s history, $124,278 as compared to a negative cash flow from operations of $284,810 at 3/31/10.

The comments are closed.